EQS-News: Announcement of an audit order by BaFin
|
EQS-News: aap Implantate AG
/ Key word(s): Statement
On April 10, 2025, aap Implantate AG ("aap" or "Company") was informed by BaFin that it had issued a notice regarding the order to initiate an audit of the published consolidated financial statements and the associated Group management report for the 2023 financial year. The company is in close contact with BaFin in order to clarify the past facts of the case transparently and promptly and to lead the audit review to a consensual conclusion in a constructive dialogue.
---------------------------------------------------------------- aap Implantate AG (ISIN DE0005066609) - General Standard/Regulated Market - All German Stock Exchanges –
About aap Implantate AG aap Implantate AG is a global medical technology company headquartered in Berlin, Germany. The company develops, manufactures and markets products for traumatology. In addition to the innovative anatomical plate system LOQTEQ®, the IP-protected portfolio includes a wide range of perforated screws. In addition, aap Implantate AG has an innovation pipeline with promising development projects, such as antibacterial silver coating technology and magnesium-based implants. These technologies address critical and not yet adequately solved problems in traumatology. In Germany, aap Implantate AG sells its products directly to hospitals, purchasing groups and affiliated clinics, while on an international level, it primarily uses a broad network of distributors in around 25 countries. In the USA, the company and its subsidiary aap Implants Inc. rely on a distribution agent and selective direct sales strategy. The shares of aap Implantate AG are listed in the General Standard of the Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit our website at www.aap.de.
There may be technical rounding differences in the figures presented in this press release, which do not affect the overall statement.
Forward-Looking Statements This release may contain forward-looking statements based on the current expectations, assumptions and forecasts of the Management Board and information currently available to it. The forward-looking statements are not to be understood as guarantees of future developments and results referred to therein. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial condition, development or performance of the Company to differ materially from the estimates given herein. These factors also include those described by aap in published reports. Forward-looking statements therefore speak only as of the date on which they are made. We undertake no obligation to update the forward-looking statements made in this release or to conform them to future events or developments.
If you have any questions, please contact: aap Implantate AG; Rubino Di Girolamo; Chairman of the Board of Directors/CEO; Lorenzweg 5; 12099 Berlin
11.04.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | aap Implantate AG |
| Lorenzweg 5 | |
| 12099 Berlin | |
| Germany | |
| Phone: | +49 (0) 30 75 019-0 |
| Fax: | +49 (0) 30 75 019-111 |
| E-mail: | info@aap.de |
| Internet: | www.aap.de |
| ISIN: | DE000A3H2101 |
| WKN: | A3H210 |
| Listed: | Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2116436 |
| End of News | EQS News Service |
|
|
2116436 11.04.2025 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | ||
| Sales1 | 11,74 | 9,33 | 12,17 | 11,52 | 11,48 | 12,20 | 0,00 | |
| EBITDA1,2 | -5,14 | -4,77 | -0,77 | -1,71 | -3,67 | -0,85 | 0,00 | |
| EBITDA-Margin3 | -43,78 | -51,13 | -6,33 | -14,84 | -31,97 | -6,97 | 0,00 | |
| EBIT1,4 | -19,77 | -7,89 | -2,61 | -3,39 | -5,19 | -2,70 | 0,00 | |
| EBIT-Margin5 | -168,40 | -84,57 | -21,45 | -29,43 | -45,21 | -22,13 | 0,00 | |
| Net Profit (Loss)1 | -19,52 | -8,79 | -2,52 | -2,56 | -5,13 | -3,63 | 0,00 | |
| Net-Margin6 | -166,27 | -94,21 | -20,71 | -22,22 | -44,69 | -29,75 | 0,00 | |
| Cashflow1,7 | -5,77 | -3,68 | -2,47 | -1,89 | -2,99 | -1,12 | 0,00 | |
| Earnings per share8 | -6,10 | -2,79 | -0,51 | -0,39 | -0,58 | -0,28 | -0,14 | |
| Dividend per share8 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: MSW
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| aap Implantate | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A3H210 | DE000A3H2101 | AG | 19,84 Mio € | 10.05.1999 | 9F4MF94Q+7M | |
| PE 2026e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| -19,29 | 0,00 | 0,00 | -0,73 | 1,90 | -17,65 | 1,63 |
|
Dividend '2023 in € |
Dividend '2024 in € |
Dividend '2025e in € |
Div.-Yield '2025e in % |
| 0,00 | 0,00 | 0,00 | 0,00% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 23.09.2025 | 06.05.2025 | 16.09.2025 | - | 30.06.2025 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| -8,85% | -13,74% | +6,30% | +5,47% | -98,65% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
